Rafarma Pharmaceuticals, Inc. (RAFA) Roars through July with Key Achievements, Kicks-off Month of August with Same Fervor
For management of Rafarma Pharmaceuticals, July was a bustling month of business strategy. The company knocked out a handful of initiatives as it continues to grow as one of Russia’s leading pharmaceutical manufacturers. In early July Rafarma entered into a new production contract for the manufacture of para-aminosalicylic acid (PAS), which will be marketed and distributed by OOO “Advance Trading,” a leading distributor of PAS in Russia who is responsible for roughly 20 percent of sales of PAS in the Russian market. According to pharmaceutical analysts at DSM Group, the PAS market in the Russian Federation topped $8.2 billion in…